2 completed. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 2 |
Follow Invasive Pulmonary Aspergillosis: new trials by email Literature Review of Invasive Pulmonary Aspergillosis trials Research Report on Invasive Pulmonary Aspergillosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment Ibrexafungerp - Invasive Candidiasis, Mucocutaneous Candidiasis | Phase 3 | Completed | Scynexis, Inc. | 233 | 2017-04-01 | 2024-11-20 |
| A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069) Posaconazole, Voriconazole, Placebo - Fungal Infections, Invasive Pulmonary Aspergillosis | Phase 3 | Completed | Merck Sharp & Dohme LLC | 585 | 2013-09-25 | 2024-01-18 |
Aspergillosis, Allergic Bronchopulmonary (1) · Blastomycosis (1) · Candidiasis, Chronic Mucocutaneous (1) · Candidiasis, Invasive (1) · Candidiasis, Vulvovaginal (1) · Coccidioidomycosis (1) · Histoplasmosis (1) · Mycoses (1)
Aspergillosis (2) · Bacterial Infections and Mycoses (2) · Infections (2) · Invasive Fungal Infections (2) · Lung Diseases (2) · Lung Diseases, Fungal (2) · Pulmonary Aspergillosis (2) · Respiratory Tract Diseases (2) · Candidiasis (1) · Chronic Disease (1) · Dermatomycoses (1) · Disease Attributes (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genital Diseases (1)
Voriconazole (1) · ibrexafungerp (1) · posaconazole (1)
Merck Sharp & Dohme LLC (1) · Scynexis, Inc. (1)
Austria (1) · Germany (1) · Netherlands (1) · Pakistan (1) · South Africa (1) · Spain (1) · United Kingdom (1) · United States (1)
2017 (1)